Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

RAS testing of colorectal carcinoma—a guidance document from the Association of Clinical Pathologists Molecular Pathology and Diagnostics Group.

Journal of clinical pathology - 1 Sept 2014

Wong Newton A C S, Gonzalez David, Salto-Tellez Manuel, Butler Rachel, Diaz-Cano Salvador J, Ilyas Mohammad, Newman William, Shaw Emily, Taniere Philippe, Walsh Shaun V

Abstract excerpt

Analysis of colorectal carcinoma (CRC) tissue for KRAS codon 12 or 13 mutations to guide use of anti-epidermal growth factor receptor (EGFR) therapy is now considered mandatory in the UK. The scope of this practice has been recently extended because of data indicating that NRAS mutations and addi...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to GTP Phosphohydrolases

Share to Precision Medicine

Share to Predictive Value of Tests

Share to Proto-Oncogene Proteins p21(ras)

Share to Quality Control

Share to ras Proteins

Source

Identifiers

PMID: 24996433
DOI: 10.1136/jclinpath-2014-202467

Genes

KRAS
EGFR
NRAS
NHS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-24996433-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

RAS testing of colorectal carcinoma—a guidance document from the Association of Clinical Pathologists Molecular Pathology and Diagnostics Group.PMID 24996433Read ↗

Progress and potential of RAS mutation detection for diagnostics and companion diagnostics.Semantic proximity Read ↗

Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy?Semantic proximity Read ↗

KRAS mutation testing of colorectal cancer for anti-EGFR therapy: dogmas versus evidence.Semantic proximity Read ↗

Liquid biopsy as a tool for KRAS/NRAS/BRAF baseline testing in metastatic colorectal cancer.Semantic proximity Read ↗

Multi-Center Evaluation of the Fully Automated PCR-Based Idylla™ KRAS Mutation Assay for Rapid KRAS Mutation Status Determination on Formalin-Fixed Paraffin-Embedded Tissue of Human Colorectal CancerSemantic proximity Read ↗

Accurate KRAS mutation testing for EGFR-targeted therapy in colorectal cancer: emphasis on the key role and responsibility of pathologists.Semantic proximity Read ↗

KRAS testing and its importance in colorectal cancer.Semantic proximity Read ↗

Tumor profiling of KRAS, BRAF, and NRAS gene mutations in patients with colorectal cancer: A Lebanese major center cohort study.Semantic proximity Read ↗

RAS genes in colorectal carcinoma: pathogenesis, testing guidelines and treatment implicationsSemantic proximity Read ↗

How close are we to standardised extended RAS gene mutation testing? The UK NEQAS evaluation.Semantic proximity Read ↗

Comparison of KRAS mutation analysis of colorectal cancer samples by standard testing and next-generation sequencing.Semantic proximity Read ↗

RAS Mutational Status Detection in Tissue, Plasma, and Stool Samples for Colorectal Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.